產(chǎn)品概述
| 產(chǎn)品名稱(Product Name) | Ret Rabbit Polyclonal Antibody |
| 描述(Description) | Rabbit Polyclonal Antibody |
| 宿主(Host) | Rabbit |
| 應用(Application) | WB,IHC-P,IF-P,IF-F,ICC/IF,ELISA |
| 種屬反應性(Reactivity) | Human,Mouse,Rat |
產(chǎn)品性能
| 偶聯(lián)物(Conjugation) | Unconjugated |
| 修飾(Modification) | Unmodified |
| 同種型(Isotype) | IgG |
| 克隆(Clonality) | Polyclonal |
| 形式(Form) | Liquid |
| 存放說明(Storage) | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| 儲存溶液(Buffer) | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% New type preservative N. |
| 純化方式(Purification) | Affinity purification |
免疫原
| 基因名(Gene Name) | RET |
| 別名(Alternative Names) | RET; CDHF12; CDHR16; PTC; RET51; Proto-oncogene tyrosine-protein kinase receptor Ret; Cadherin family member 12; Proto-oncogene c-Ret |
| 基因ID(Gene ID) | 5979 |
| 蛋白ID(SwissProt ID) | P07949 |
產(chǎn)品應用
| 稀釋比(Dilution Ratio) | WB 1:500-1:2000, IHC-P 1:100-1:300, IF-P/IF-F/ICC/IF 1:200-1:1000, ELISA 1:20000.Not yet tested in other applications. |
| 蛋白分子量(Molecular Weight) | 170kDa |
研究背景
ret proto-oncogene(RET) Homo sapiens This gene, a member of the cadherin superfamily, encodes one of the receptor tyrosine kinases, which are cell-surface molecules that transduce signals for cell growth and differentiation. This gene plays a crucial role in neural crest development, and it can undergo oncogenic activation in vivo and in vitro by cytogenetic rearrangement. Mutations in this gene are associated with the disorders multiple endocrine neoplasia, type IIA, multiple endocrine neoplasia, type IIB, Hirschsprung disease, and medullary thyroid carcinoma. Two transcript variants encoding different isoforms have been found for this gene. Additional transcript variants have been described but their biological validity has not been confirmed. [provided by RefSeq, Jul 2008],catalytic activity:ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate.,disease:Chromosomal aberrations involving RET are a cause of thyroid papillary carcinoma (PACT) [MIM:188550]. Inversion inv(10)(q11.2;q21) generates the RET/CCDC6 (PTC1) oncogene; inversion inv(10)(q11.2;q11.2) generates the RET/NCOA4 (PTC3) oncogene; translocation t(10;14)(q11;q32) with GOLGA5 generates the RET/GOLGA5 (PTC5) oncogene; translocation t(8;10)(p21.3;q11.2) with PCM1 generates the PCM1/RET fusion; translocation t(6;10)(p21.3;q11.2) with RFP generates the Delta RFP/RET oncogene; translocation t(1;10)(p13;q11) with TRIM33 generates the TRIM33/RET (PTC7) oncogene; translocation t(7;10)(q32;q11) with TIF1 generates the TIF1/RET (PTC6) oncogene. The PTC5 oncogene has been found in 2 cases of PACT in children exposed to radioactive fallout after Chernobyl.,disease:Defects in RET are a cause of congenital central hypoventilation syndrome (CCHS) [MIM:209880]; also known as congenital failure of autonomic control or Ondine curse. CCHS is a rare disorder characterized by abnormal control of respiration in the absence of neuromuscular or lung disease, or an identifiable brain stem lesion. A deficiency in autonomic control of respiration results in inadequate or negligible ventilatory and arousal responses to hypercapnia and hypoxemia.,disease:Defects in RET are a cause of Hirschsprung disease (HSCR) [MIM:142623]. HSCR is a genetic disorder of neural crest development characterized by the absence of intramural ganglion cells in the hindgut, often resulting in intestinal obstruction. Occasionally, MEN2A or FMTC occur in association with HSCR.,disease:Defects in RET are a cause of pheochromocytoma [MIM:171300]. The pheochromocytomas are catecholamine-producing, chromaffin tumors that arise in the adrenal medulla in 90% of cases. In the remaining 10% of cases, they develop in extra-adrenal sympathetic ganglia and may be referred to as "paraganglioma." Pheochromocytoma usually presents with hypertension. Approximately 10% of pheochromocytoma is hereditary. The genetic basis for most cases of non-syndromic familial pheochromocytoma is unknown.,disease:Defects in RET are a cause of renal adysplasia [MIM:191830]; also known as renal agenesis or renal aplasia. Renal agenesis refers to the absence of one (unilateral) or both (bilateral) kidneys at birth. Bilateral renal agenesis belongs to a group of perinatally lethal renal diseases, including severe bilateral renal dysplasia, unilateral renal agenesis with contralateral dysplasia and severe obstructive uropathy.,disease:Defects in RET are the cause of medullary thyroid carcinoma (MTC) [MIM:155240]. MTC is a rare tumor derived from the C cells of the thyroid. Three hereditary forms are known, that are transmitted in an autosomal dominant fashion: (a) multiple neoplasia type 2A (MEN2A), (b) multiple neoplasia type IIB (MEN2B) and (c) familial MTC (FMTC), which occurs in 25-30% of MTC cases and where MTC is the only clinical manifestation.,disease:Defects in RET are the cause of multiple neoplasia type 2A (MEN2A) [MIM:171400]; also called multiple neoplasia type 2 (MEN2). MEN2A, the most frequent form of MTC, is an inherited cancer syndrome characterized by MTC, phaeochromocytoma and/or hyperparathyroidism.,disease:Defects in RET are the cause of multiple neoplasia type 2B (MEN2B) [MIM:162300]. MEN2B is an uncommon inherited cancer syndrome characterized by predisposition to MTC and phaeochromocytoma which is associated with marfanoid habitus, mucosal neuromas, skeletal and ophtalmic abnormalities, and ganglioneuromas of the intestine tract. Then the disease progresses rapidly with the development of metastatic MTC and a pheochromocytome in 50% of cases.,disease:Defects in RET may be a cause of colorectal cancer (CRC) [MIM:114500].,function:Probable receptor with tyrosine-protein kinase activity; important for development.,polymorphism:The Cys-982 polymorphism may be associated with an increased risk for developing Hirschsprung disease.,PTM:Autophosphorylated on C-terminal tyrosine residues upon ligand stimulation.,PTM:Phosphorylated.,similarity:Belongs to the protein kinase superfamily. Tyr protein kinase family.,similarity:Contains 1 cadherin domain.,similarity:Contains 1 protein kinase domain.,subunit:Phosphorylated form interacts with the PBT domain of DOK2, DOK4 and DOK5.,
研究領域
Endocytosis;Pathways in cancer;Thyroid cancer;
關鍵字: RET;Ret;Rabbit;Polyclonal;Antibody;一抗
武漢恩璣生命科技有限公司(EnkiLife)是一家深耕生命科學,專注細胞生物學和免疫學科研試劑的研發(fā)、生產(chǎn)與銷售的生物技術企業(yè),在全球100多個國家和地區(qū)開展業(yè)務,致力于為科研工作者提供高質(zhì)量的產(chǎn)品和卓越的客戶服務,推動生命科學的發(fā)展。
EnkiLife的產(chǎn)品線涵蓋細胞系、原代細胞、細胞培養(yǎng)基、血清、細胞檢測試劑盒、重組靶點蛋白、細胞因子、重組抗體、ELISA試劑盒、生化試劑盒等,并提供技術服務與定制開發(fā),覆蓋了生命科學研究的各大關鍵領域,包括細胞生物學、癌癥、免疫學、神經(jīng)科學、心血管疾病、干細胞、表觀遺傳學、內(nèi)分泌、蛋白質(zhì)組學、代謝組學等,全方位滿足您的實驗需求,讓您享受科研的樂趣!
公司現(xiàn)已建立四大技術平臺:
EnCyto?細胞培養(yǎng)及檢測平臺:擁有細胞系庫(500+)、原代細胞庫(500+)、基礎培養(yǎng)基和完全培養(yǎng)基(1200+)
EnkiPro?重組蛋白平臺:現(xiàn)貨產(chǎn)品2000+,可提供定制化表達服務
EnAb?重組抗體平臺:重組兔單抗(3000+),可提供定制化和標記服務
EnKits?試劑盒開發(fā)平臺:可提供優(yōu)質(zhì)的ELISA試劑盒、配套試劑、抗體對、生化試劑盒等相關產(chǎn)品
EnkiLife在生產(chǎn)管理方面引入ISO9001質(zhì)量管理體系和信息化、自動化的管理工具,擁有高效穩(wěn)定的交付能力,與全球知名品牌建立了緊密的合作。
EnkiLife始終堅持以技術創(chuàng)新為驅(qū)動,以匠心鑄就品質(zhì),以品質(zhì)服務客戶。
我們期待與更多的全球科研工作者和企業(yè)攜手合作,共同推動生命科學領域的進步與發(fā)展。